Abbott Diagnostics Exhibits POC Diagnostics Solutions at AACC
|
By LabMedica International staff writers Posted on 05 Aug 2019 |

Image: The ID NOW isothermal system for the qualitative detection of infectious diseases (Photo courtesy of Abbott Diagnostics).
Abbott Diagnostics (Lake Bluff, IL, USA) exhibited its range of rapid Point-of-Care (POC) diagnostics solutions at the 71st AACC Annual Scientific Meeting & Clinical Lab Expo held in Anaheim, California, USA. The annual event held by the American Association for Clinical Chemistry (AACC) showcased the cutting-edge science and technology shaping the future of laboratory medicine.
At AACC 2019, Abbott exhibited ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing users to make effective clinical decisions sooner. ID NOW is significantly faster than other molecular methods and more accurate than conventional rapid tests and can have a positive impact in any healthcare setting.
Abbott also showcased its Afinion 2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the POC. Designed to enable simple and fast on-the-spot testing, regardless of the sample type, the Afinion System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP. By delivering accurate results during patient consultation, it eliminates the need to send patients to the lab or spend time tracking down their results for improved patient management.
Abbott also demonstrated its RALS POC Data management system, which provides immediate and remote access to patient and quality control results from the POCT devices being used. Unlike data management solutions that use a device-specific data manager between the device and their system, the RALS System can manage all devices, all patient results, all operators, all consumables and all reports —from a single-system solution.
At AACC 2019, Abbott exhibited ID NOW, a rapid, instrument-based, isothermal system for the qualitative detection of infectious diseases. The ID NOW isothermal nucleic acid amplification technology provides molecular results in just minutes, allowing users to make effective clinical decisions sooner. ID NOW is significantly faster than other molecular methods and more accurate than conventional rapid tests and can have a positive impact in any healthcare setting.
Abbott also showcased its Afinion 2 Analyzer, a compact, rapid, multi-assay analyzer that provides valuable near patient testing at the POC. Designed to enable simple and fast on-the-spot testing, regardless of the sample type, the Afinion System makes it fast and easy to test quantitative determinations of HbA1c, Lipid Panel, ACR, and CRP. By delivering accurate results during patient consultation, it eliminates the need to send patients to the lab or spend time tracking down their results for improved patient management.
Abbott also demonstrated its RALS POC Data management system, which provides immediate and remote access to patient and quality control results from the POCT devices being used. Unlike data management solutions that use a device-specific data manager between the device and their system, the RALS System can manage all devices, all patient results, all operators, all consumables and all reports —from a single-system solution.
Latest AACC 2019 News
- Instrumentation Laboratory Presents New IVD Testing System
- Quidel Welcomes Newest Member of Triage Family
- ERBA Mannheim Unveils Next-Generation Automation
- Roche Demonstrates How Health Networks Are Driving Change in Labs and Beyond
- BioMérieux Spotlights Diagnostic Solutions in Use of Antibiotics
- Thermo Shows New Clinical Innovations
- Randox Launches New Innovations
- Streck Introduces Three New Antibiotic Resistance Detection Kits
- EKF Diagnostics Highlights Assay for Diabetes Patient Monitoring
- Sysmex America Exhibits New Products, Automation and Quality Solutions
- BBI Solutions Showcases Mobile Solutions Capabilities at AACC 2019
- MedTest Dx Releases New Product Line for Drugs of Abuse Testing
- Mesa Biotech Launches Molecular Test System at AACC 2019
- Ortho Clinical Diagnostics Highlights Groundbreaking Lab Technology
- Beckman Coulter Demonstrates Latest Innovations in Lab Medicine
- Orion Diagnostica Showcases Range of Products in Anaheim
Channels
Clinical Chemistry
view channel
Blood Test Tracks Transplant Health Using Donor DNA
Organ transplantation offers life-saving treatment for patients with end-stage disease, but complications such as rejection remain a constant risk. Monitoring transplanted organs typically relies on invasive... Read more
AI Sensor Detects Neurological Disorders Using Single Saliva Drop
Neurological disorders such as Parkinson’s disease and Alzheimer’s disease often develop gradually and present subtle symptoms in their early stages. Because early signs are frequently vague or atypical,... Read moreMolecular Diagnostics
view channel
AI-Based Liquid Biopsy Detects Liver Fibrosis, Cirrhosis and Chronic Disease Signals
Liver fibrosis and cirrhosis often develop silently for years before symptoms appear, making early diagnosis difficult. Detecting these conditions earlier could allow treatment before irreversible damage... Read moreBlood Test Could Detect Pre-Eclampsia Before Symptoms Appear
Pre-eclampsia is a dangerous pregnancy complication characterized by sudden high blood pressure that can threaten the lives of both mother and baby. Affecting about five percent of pregnancies worldwide,... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more
Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
Myasthenia gravis is a rare autoimmune disorder in which immune attack at the neuromuscular junction causes fluctuating weakness that can impair vision, movement, speech, swallowing, and breathing.... Read more
New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read moreBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read moreMicrobiology
view channel
Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
Direct-to-consumer gut microbiome kits promise personalized insights by profiling fecal bacteria and generating health readouts, but their analytical accuracy remains uncertain. A new study shows that... Read more
WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
Tuberculosis (TB) remains one of the world’s leading infectious disease killers, yet millions of cases go undiagnosed or are detected too late. Barriers such as reliance on sputum samples, limited laboratory... Read morePathology
view channel
Novel mcPCR Technology to Transform Testing of Clinical Samples
DNA methylation is an important biological marker used in the diagnosis and monitoring of many diseases, including cancer. These chemical modifications to DNA influence gene activity and can reveal early... Read more
Sex Differences in Alzheimer’s Biomarkers Linked to Faster Cognitive Decline
Sex differences in Alzheimer’s disease present ongoing diagnostic challenges, with women often experiencing a disproportionate disease burden even when preclinical amyloid-beta levels are similar to men.... Read moreTechnology
view channel
AI Model Outperforms Clinicians in Rare Disease Detection
Rare diseases affect an estimated 300 million people worldwide, yet diagnosis is often protracted and error-prone. Many conditions present with heterogeneous signs that overlap with common disorders, leading... Read more
AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
Periprosthetic joint infection (PJI) is a rare but serious complication affecting 1% to 2% of primary joint replacement surgeries. The condition occurs when bacteria or fungi infect tissues around an implanted... Read moreIndustry
view channel
Agilent Technologies Acquires Pathology Diagnostics Company Biocare Medical
Agilent Technologies (Santa Clara, CA, USA) has entered into a definitive agreement to acquire Biocare Medical (Pacheco, CA, USA), expanding its pathology portfolio through the addition of highly complementary... Read more
Cepheid Joins CDC Initiative to Strengthen U.S. Pandemic Testing Preparednesss
Cepheid (Sunnyvale, CA, USA) has been selected by the U.S. Centers for Disease Control and Prevention (CDC) as one of four national collaborators in a federal initiative to speed rapid diagnostic technologies... Read more
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more









